Esbriet Plus Anti-PD-L1 Slows Lung Cancer and Fibrosis in Mouse Study

Esbriet Plus Anti-PD-L1 Slows Lung Cancer and Fibrosis in Mouse Study

284767

Esbriet Plus Anti-PD-L1 Slows Lung Cancer and Fibrosis in Mouse Study

In mouse models of lung cancer and fibrosis, a combination of Esbriet (pirfenidone) and anti-PD-L1 therapy strengthened an anti-tumor immune response and reduced tumor growth, while also easing pulmonary scarring in the animals. This combination therapy might be useful in treating lung cancer that develops in people with idiopathic pulmonary fibrosis (IPF), and further testing is warranted, the research team wrote. The study, “Pirfenidone facilitates immune infiltration and enhances the antitumor efficacy of PD-L1 blockade in mice,”…

You must be logged in to read/download the full post.